Although stem cell factor (SCF) has been identified as a critical cytokine for the development of human mast cells from their progenitors, the effects of other cytokines on human mast cells are less well understood. We examined the effects of several cytokines on the survival of human mast cells of 100% purity generated in suspension cultures of umbilical cord blood mononuclear cells in the presence of 100 nglmL recombinant human (rh) SCF and interleukin-6 (IL-6). Mast cells suspended in conventional serum-containing medium died over a period of 2 to 6 days after the withdrawal of SCF and IL-6. The cells became pyknotic and underwent DNA fragmentation characteristic of apoptosis. The addition of SCF, IL-3, IL-4, IL-5, or IL-6 to the cultures in both serumcontaining and serum-free medium prolonged their survival in a dose-dependent manner. Some other cytokines, such as IL-2, IL-9, [L-10, IL-11, tumor necrosis factor-a, transforming AST CELLS ARE UNIQUE immune cells that release a variety of chemical mediators, such as histamine, leukotorienes,' and cytokines?" induced by the reaction of allergen with cell-bound IgE antibodies. Progenitors of human mast cells have been shown to be derived from CD34+ cells in bone marrow.$ Stem cell factor (SCF) is known to act as a major growth and differentiation factor for human mast cells from progenitors in cord blood mononuclear bone m a r r~w ,~.~ and fetal liver: whereas several murine cytokines, such as SCF, interleukin-3 (IL-3), IL-4, IL-9, and IL-10, promote differentiation and proliferation of mouse mast
In human mast cells, it is of interest to determine whether cytokines other than SCF are involved in the development of mast cells and affect their function. Kirshenbaum et alS3' have reported that IL-3 alone and in combination with SCF promoted the growth and survival of human mast cells from bone marrow. However, there is little information about the effects of cytokines other than SCF on human mast cells, partly because sufficient amounts of pure human mast cells have yet to be obtained from lungs, skin, or tonsils or developed in vitro from their progenitors.
Furitsu et al" first succeeded in developing human mast cells in vitro by coculture of mononuclear cord blood cells and Swiss albinol3T3 fibroblasts. Subsequently, we established a method for long-term suspension culture of human mast cells that were developed from mononuclear cord blood cells in the presence of recombinant human (rh) SCF. 6 We recently succeeded in developing pure human mast cells efficiently from CD34+I6 or mononuclear cell^'^^'^ of cord blood in the presence of SCF and IL-6. IL-6 might act synergistically to expand the number of human mast cells progenitors and to promote their differentiation. All these mast cells were immunohistologically positive for tryptase, whereas only 20% to 30% of the cells were immunoreactive for chym a~e . '~. '~ Human mast cells developed from cord blood cells by SCF and IL-6 could be sensitized with IgE and released mediators upon challenge with anti-IgE antib~dy.'~,'~ They are functionally active and more like tryptase-positive mast cells (MCT)l8 seen in human lung and gastrointestinal mu- growth factor-fi1, and nerve growth factor, had no survivalpromoting effect at 100 ng/mL. Preincubation of mast cells with SCF, IL4, IL-5, or IL-6 for 24 hours during sensitization with IgE enhanced IgElanti-lgE antibody-induced histamine release from mast cells, whereas IL-3 showed a negligible effect. Polymerase chain reaction amplification of a-chains of IL-3 receptor (R), I L 4 R, 11-5 R, and IL-6 R yielded products of the correct size predicted from the sequence of each receptor. The binding assay using '251-labeled IL-3 indicated that these mast cells bear receptors for IL-3. These findings suggest that IL-3, IL-4, IL-5, and IL-6, which are mainly produced by T-helper 2 lymphocytes, might regulate the functions of human mast cells in vivo via specific receptors in allergic reactions. 0 1995 by The American Society of Hematology.
cosa. The development of this culture method enabled us to study the biology of human mast cells more precisely.
In the present study, we examined the in vitro survivalpromoting activity of several cytokines on human mast cells of 100% purity. Our data showed that IL-3, IL-4, IL-5, and IL-6 as well as SCF promote the in vitro survival of human mast cells developed from cord blood mononuclear cells in the presence of SCF and L-6. Using reverse transcriptasepolymerase chain reaction (RT-PCR) and binding assays, we showed that cultured human mast cells express mRNAs of IL-3 receptor (R), IL-4 R, IL-5 R, and L-6 R a-chains and have specific binding sites for at least IL-3. In this report, we show the new aspects of the human cytokine network in allergic reactions through the interactions between human mast cells and T-helper 2 (Th2)-type cytokines.
MATERIALS AND METHODS
Cell culture. The culture methods of human mast cells that had been established previously by the several investigator^^^'^"' were modified. Mononuclear cells were obtained from heparinized umbilical cord blood and suspended in a-minimum essential medium (a-
3706
YANAGIDA ET AL MEM; GIBCO-BRL Laboratories, Grand Island, NY) supplemented with 20% fetal calf serum (FCS; HyClone Laboratories, Logan, UT); 1% bovine serum albumin (BSA; Sigma Chemicals, St Louis, MO); 10 yg/mL deoxyadenosine, deoxyguanosine, deoxycytidine, adenosine, guanosine, cytidine, thymidine, and uridine (Sigma); 100 U/ mL penicillin (Sigma); and 50 pg/mL streptomycin (Sigma). The cell suspensions were cultured in the presence of 100 ng/mL rhSCF and rhIL-6 (Kirin Brewery, Tokyo, Japan). Nonadherent cells were harvested weekly after gently pipetting the culture media over the bottom of a flask and resuspending the cells in culture media, half of which was replaced. Total cell numbers were counted using hemacytometers (Kayagaki Clinical and Scientific Equipment, Tokyo, Japan), and the purity of mast cells was determined by staining with May-Grunwald and Giemsa reagents every 2 weeks. The immunoperoxidase staining for tryptase and chymase" was performed every 4 weeks Survival assay. Cultured human mast cells were washed twice in 20% FCS-containing a-MEM and then replated in 96-well culture dishes (Becton Dickinson, Lincoln Park, NJ) at a density of 2 X IO4 cells in 200 pL on day 0. These cells were maintained at 37°C in a humidified atmosphere of 95% air-5% CO2 in each medium supplemented with various cytokines for an additional 4 to 6 days at concentrations that varied with the particular experiment. Cell viability was assessed at various intervals thereafter according to the trypan blue exclusion test. In the serum-free survival assays, mast cells were washed in FCS-free a-MEM and BSA-coated 96-well culture dishes were prepared by incubation of dishes at 37°C for 2 hours after 200 pL of 5% BSA was added into each well.
Cytokines. The sources of cytokines were as follows: rhIL-2, rhIL-3, rhIL-4, rhIL-5, rhIL-10, and rhIL-l1 from Genzyme (Cambridge, MA); rhIL-9 from R&D Systems (Minneapolis, MN); rh tumor necrosis factor-a (TNF-a) from Upstate Biotechnology (Lake Placid, NY); rh nerve growth factor (NGF) from Austral Biologicals (San Ramon, CA); and rh transforming growth factor-p1 (TGF-PI) from Kirin Brewery.
Electron microscopy (EM). Cells maintained in 20% FCS-containing medium supplemented with or without 100 ng/mL rhSCF were collected on day 2, fixed in 2% glutaraldehyde for 1.5 hours, and washed in 0.1 m o m sodium phosphate buffer. The cells were then postfixed in 1% osmic acid in 0.1 m o m sodium phosphate buffer for 1.5 hours and embedded in epoxy resin. These blocks were processed for EM studies as described previously.2o
In situ detection of DNA fragmentation. Some samples of the cells collected for EM were subjected to cytocentrifugation (Shandon, Pittsburgh, PA) on glass slides, dried, and fixed promptly in Carnoy's fixative overnight. After washing with water, slides were incubated at 37°C in 2.5 pg/mL proteinase K (Sigma) for 15 minutes, washed with phosphate-buffered saline (PBS), and dehydrated by passage through a series consisting of SO%, 75%, 95%, and 100% ethanol. In situ detection of DNA fragmentation was performed using an immunoperoxidase staining kit (ApopTag; Oncor, Gaitbersburg, MD).*' Briefly, slides were quenched in 2% hydrogen peroxidase to block nonspecific staining and then reacted with a mixture of terminal deoxynucleotidyl transferase (TdT), digoxigenin-dUTP, and dATP to label the 3'-OH ends of DNA. Digoxigenin incorporated into the tails of DNA molecules was identified by immunohistochemical procedures. The nuclei of multiple DNA fragment-containing cells were stained reddish brown. Cell nuclei were counterstained with methyl green.
Histamine release. BSA-coated 24-well culture dishes were prepared by incubation of dishes (Becton Dickinson) at 37°C for 2 hours after 1 mL of 5% BSA was added to each well. Cultured cells were washed twice in FCS-free a " E M and incubated with 10 pg/ mL human IgE (a generous gift from Dr Kimishige Ishizaka, La Jolla Institute for Allergy and Immunology, La Jolla, CA) for 24 hours at 37°C under FCS-free conditions with or without rhSCF, rhIL-3, rhIL-4, rhIL-5, or rhIL-6 (1, 10, and 100 ng/mL) in BSAcoated 24-well culture dishes. After washing, the cells were incubated at 37°C for 30 minutes with 4 p g h L ana-IgE antibody (Chemicon, Temecula, CA). Histamine content in Supernatants and that remaining in cell pellets was determined by the automated technique of Siraganian?' The percentage of enhancement of histamine release was calculated using the following formula: (% stimulated release -% control release/% control release) X 100.
RNA preparation. Cellular mRNA was isolated from cultured
For personal use only. on April 29, 2017. by guest www.bloodjournal.org From IL-3, -4, -5, AND -6 PROMOTE MAST CELL SURVIVAL 3707 human mast cells and the U-937 cell line23 using a QuickPrep Micro mRNA Purification Kit (Pharmacia Biotech, Piscataway, NJ). Briefly, extraction buffer containing a high concentration of guanidinium i~orhiocyanate~~ was added to the cell pellet. Elution buffer was then added. After centrifugation, Supernatants were transferred to microcentrifuge tubes containing oligo(dT)-cellulose. The polyadenylated RNA bound to the oligo(dT)-cellulose pellet was then washed sequentially with high-salt buffer and eluted with low-salt buffer. The mRNA pellet was then precipitated in ethanol, and the purified mRNA was resuspended in water.
Oligonucleotide primers. Primers, the sources of which are not described below, were prepared in the oligonucleotide synthesis core at Kirin Brewery. The primers used were as follows: RT-PCR. First-strand cDNAs were synthesized from the purified mRNAs using a first-strand cDNA synthesis kit (Pharmacia). Briefly, 1 .O pg of RNA in 11 pL of reaction buffer (murine reverse transcriptase, RNA guard, BSA, dATP, dCTP, dGTP, and d'lTP), 1 pL of 200 mmoVL dithiothreitol (D'IT), and 0.2 pg of random primer were mixed in a final volume of 33 pL and incubated at 37°C for 1 hour. One microliter of the double-stranded products from human mast cells and the U-937 cell line, human IL-6 R probe (Clontech), human bone marrow cDNA (Clontech), or water was mixed with 2 pL of 1OX Taq/RT buffer (1X Taq/RT buffer consists of 10 mmoVL gelatin; Takara Biomedical, Shiga, Japan), 1.6 pL of 2.5 mmoVL dNTP mixture (Takara), 1 pL of 20 MmoYL of each of the primers of interest, and 1 U Taq polymerase (Takara). The reaction mixture underwent thermal cycling at 95°C for 1 minute, 57°C for 1 minute, and 72°C for 1 minute for 30 cycles and a final 7 minutes of extension at 72°C. PCR products were analyzed by agarose gel electrophoresis.
Binding assay. rh IL-3 was radiolabeled with Bolton & Hunter reagents (ICN Biomedicals, Costa Mesa, CA), as described previously.*' Briefly, aliquots of 5 pg rhIL-3 were incubated in 0.5 mCi of reagent at 4°C for 15 hours. The reaction was then terminated by the addition of 250 pg glycine. Radiolabeled rhIL-3 was purified by a single gel-filtration step on Parmacia PD-IO G25 M columns in PBS containing 0.1% gelatin. The specific radioactivity of 1z51-labeled rhIL-3 was measured by self-displacement analysis26 with TF-1 cellsz5 as IL-3 R bearing targets. For binding analyses, 5 x lo6 cells were incubated with '2'I-labeled rhIL-3 in 100 pL Hank's balanced salt solution containing 10% FCS. After 3 hours of incubation at 15°C in 1.5-mL Eppendorf tubes, the incubation mixtures Tris-HC1, pH 8.3, 50 ~o V L KCl, 1.5 ~o V L MgC12, and 0.001%
were transferred onto 350 pL precooled FCS in 0.5 mL polyethylene centrifuge tubes and centrifuged for 1 minute. Medium and serum was then removed by aspiration and the radioactivity of the cell sediment was counted in a gamma counter. Nonspecific binding of radiolabeled rhIL-3 was quantified in the presence of an at least 200-fold excess of unlabeled rhIL-3.
RESULTS
Development of human mast cells by SCF and IL-6. The growth pattern of cord blood mononuclear cells in suspension cultures in the presence of SCF and L -6 is shown in Table 1 . The proportion of tryptase-positive cells in the cultures was in agreement with the proportion of mast cells identified by May-Griinwald-Giemsa staining. During the first 4 weeks, large numbers of differentiated cells, including neutrophils, macrophages, monocytes, and basophils, as well as mast cells, were generated. Beyond 8 weeks, the purity of mast cells reached almost 100%, and then the viability was constantly more than 95%. Apoptotic cells were seldom or never observed in the cultures under phase-contrast microscopy. The proportion of chymase-positive cells recovered from the cultures varied depending on the cord blood specimens used (15% to 85% in the period of 16 weeks).
Apoptosis of cultured human mast cells afrer withdrawal
of SCF and ZL-6. We initially determined the time course of viability of cultured human mast cells after withdrawal of rhSCF and rhIL-6. Human mast cells cultured for more than 15 weeks were used for experiments. In the absence of SCF and IL-6, the viability of the cells maintained in serumcontaining medium declined rapidly between day 2 and day 6 (Fig 1) . In contrast, the viability was perfectly maintained for 6 days in the presence of 100 ng/mL SCF or both 100 ng/mL SCF and IL-6. The viability of cells in the presence of 100 n g h L IL-6 alone gradually declined but was higher than that cultured in the absence of any cytokine. A large number of mast cells cultured in serum-containing medium in the absence of any cytokine after day 4 were smaller than normal and had a wrinkled appearance under phase-contrast microscopy. To determine whether such cell death was caused by apoptosis, we observed the process of cell death morphologically by light and electron microscopy and examined in situ DNA fragmentation of the cells. As shown in Fig 2A through D , light microscopical and ultrastructural analysis showed that a typical dying mast cell became pyknotic with a wrinkled membrane and condensation and clumping of chromatin after 2 days. Furthermore, only the nuclei of dying mast cells in the absence of SCF and IL-6 were stained reddish brown (Fig 2E and F) , with evidence of a multitude of DNA fragmentations, because the intensity of the staining is dependent on the amount of digoxigenin incorporated into the 3'-OH ends of DNA fragments.
Survival-promoting activities of SCF, IL-3, IL-4, IL-5,
and ZL-6 on cultured human mast cells. We examined the effects of the 12 cytokines SCF, IL-2, E-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-11, TNF-a, TGF-01, and NGF on the survival of cultured human mast cells in serum-containing medium. Almost 100% of the cells remained viable in the presence of 100 ng/mL SCF, and the addition of 100 ng/mL alone, whereas 100 nglmL L-2, L-9. L-IO, IL-II, TNFa. TGF-PI, and NGF showed no significant effect (Fig 3) .
During the experiment, total cell numbers (viable and dead cells) did not increase and the cells were shown not to proliferate by oxidation-reduction indicator assay (AlamarBlue shown). Remaining viable cells were well-rounded, exbibAssay; BioSource International, Camarillo. CA, data not ited a bright appearance under phase-contrast microscopy, and were all stained immunohistologically for tryptaye (data not shown). Viability of the cells in the presence of 1 0 0 ngl mL L-3, IL-4. IL-5, or IL-6 gradually declined between day 4 and day 6 and did not improve even when the cytokines were added back to the cultures at 100 ng/mL on day 4 (data not shown).
survival of mast cells in detail, we examined the dose-reTo assess the effect of SCF, IL-3, IL-4. IL-5, and K-6 on sponse of the activity in the presence or absence of serum.
BSA-coated 96-well plates were used in this experiment because mast cells were too adherent to conventional plastic shown in Fig 4A and B , the survival-promoting activity of plates to be collected easily in the absence of serum. As at 100 nglmL. but IL-3, IL-4, and L 6 remained effective IL-3, IL4, IL-5. and IL-6 was less strong than that of SCF at lower concentrations than SCF. The dose-reaction curve of IL-5 was sharp and similar to that of SCF. These cytokines showed survival-promoting activity even under serum-free conditions. Twenty percent FCS was shown to have a slight favorable effect on the survival of mast cells by itself and also showed synergistic activity with some other cytokines. To test the possibility that IL-3, IL-4, IL-5, and IL-6 as well as SCF act also to enhance IgE-mediated histamine release, mast cells were sensitized for 24 hours with human IgE under FCS-free conditions with or without SCF, IL-3, IL-4, IL-5, or IL-6 at 100 nglmL, and the sensitized cells were challenged with anti-IgE antibody. As shown in Fig 5A, SCF, IL-4, IL-5, and IL-6 enhanced IgE-mediated histamine release significantly at 100 ngImL, whereas IL-3 showed no significant effect in comparison with cytokine-untreated control (n = 4). As shown in Fig 53, the effects of the cytokines on histamine release were dose-dependent, with maximum effects observed with 100 ng/mL of the cytokines. The control cells spontaneously released less than 5% histamine without challenge, and any cytokine did not induce histamine release by itself (data not shown). R were amplified by PCR. Message of the expected size was detected for IL-3 R, IL-4 R, IL-5 R, and IL-6 R, whereas those for G-CSF R and c-fms were not detected (Fig 6) . We examined the expression of IL-3 R on cultured mast cells by binding assay using '251-radiolabeled IL-3, because 100 - For IL-3, -4, -5, AND - Valent et a127 reported that they detected no IL-3-binding sites on either human lung mast cells or a human mast cell line (HMC-l)." The optimal concentration of lZ5I-radiolabeled IL-3 was determined in a preliminary experiment using 371 1 TF-1 cells (data not shown). When TF-1 cells were incubated with 1z51-radiolabeled IL-3 at the optimal concentration, the total and nonspecific binding rates were 9,185 and 3,260 c p d 5 X IO6 cells, respectively (the data are means of duplicate experiments). Mast cells were incubated with I2%radio-labeled IL-3, and total and nonspecific binding rates were quantified in the presence or absence of nonradiolabeled competitor. The nonspecific binding rate (3,686 -C 430 c p d S x 10' cells) was apparently less than the total binding rate (6,582 2 340 cpm/S X lo6 cells), as shown in Fig 7. The results of the binding assay indicated that human mast cells express IL-3 R on their surfaces.
Expression
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DISCUSSION
SCF is known to be a critical factor for the development of human mast cell^^.^ and to enhance IgE-mediated degranulation of these cells.7~29~30 In this report, we confirmed that SCF is also a strong survival factor for human mast cells, as predicted. To exclude the effects of other-lineage cells, we used pure cultured human mast cells developed from cord blood mononuclear cells in the presence of SCF and IL-6. After withdrawal of SCF and IL-6, mast cells died rapidly, showing several changes typical of apoptosis. The results of the present study suggest that SCF is an important mediator in the regulation of apoptosis of human mast cells. SCF promoted the survival of mast cells in vitro sharply in a dose-dependent manner, and this may also be representative of the mechanism of regulation of the size of mast cell populations in vivo. Possibly, the long-term survival of human mast cells in vivo may be maintained by cell-bound SCF, which is produced by fibroblasts or stroma cells. As expected from the results of previous report^,^^" these mast cells were shown to express c-kit on their surfaces by flow cytometric analysis (data not shown).
According to a previous report, no cytokine except SCF showed a remarkable effect on the development of human mast cells from their progenitor^.^ IL-4 was shown to downregulate the expression of c-kit on the HMC-1 cell line and human mast cells from fetal li~e3~.'' and to inhibit certain aspects of development of human mast cells in long-term culture. However, we found that L -3 , IL-4, IL-S, and IL-6 promoted the survival of human mast cells in vitro in both serum-containing and serum-free medium. FCS showed a slight favorable effect on the survival of human mast cells by itself and acted synergistically with some cytokines. This effect was likely caused by bovine SCF and various nutrients present within serum. The activity of 20% FCS is supposed to be equivalent to that of approximately 3 ng/mL SCF on the basis of the work of Shiohara et al.34 IL-3, IL-4, IL-S, and IL-6 likely promote the survival of mast cells directly without involvement of any autocrine factors, because the survival-promoting activity of these factors did not depend on the density of mast cells. Some cytokines, such as SCF,3557 IL-3,38 and NGF,'9 have been reported to promote the survival of rodent mast cells in vitro by suppressing apoptosis. In the present study, NGF showed no effect on the survival of human mast cells.
Preincubation of mast cells with some of these cytokines, such as SCF, IL-4, IL-S, and IL-6, for 24 hours was shown to upregulate IgE-mediated histamine release significantly. Some investigators previously reported that a brief incubation ( I O to 45 minutes) of human lung," skin,'" and cultured7 mast cells with SCF enhanced IgE-mediated histamine release remarkably. We also observed that the incubation of mast cells with SCF ( I , 10, and 100 ng/mL) for I O minutes before challenge enhanced IgE-mediated histamine release more than 2 times, whereas that with IL-3, IL-4, IL-S, or IL-6 ( I , IO, and 100 ng/mL) showed no significant effect (data not shown). The mechanism of enhancement of IgEmediated histamine release induced by preincubation with the cytokines for 24 hours remains to be clarified. The cytokines might affect the signal transduction pathway of IgEmediated degranulation or possibly enhance the expression of Fc c RI on the cells during sensitization. It is of great interest that IL-3, IL-4. IL-S, and IL-6 are all produced by Th2 lymphocytes (IL-3 is produced by both Th I and Th2 lymphocytes),J".4' which play an important role in allergic inflammatory responses by enhancing the production of IgE antibodies and promoting the development of eosinophils and basophils." The effects of IL-3, IL-4, IL-S, and IL-6 on human mast cells described above agree well with the proposal that Th2-type cytokines promote allergic reactions by regulating various immune cells. At local sites in allergic inflammation, IL-3, IL-4, IL-S, and 1L-6 are likely present at high concentrations, and so these cytokines might also influence the survival and function of human mast cells in vivo.
In addition, these cultured human mast cells were shown to express mRNAs of IL-3 R, IL-4 R, IL-S R, and IL-6 R a-chains and to have specific binding sites for IL-3. That crchains of IL-3 R, IL-4 R, IL-S R, and IL-6 R mRNAs were detected in the mast cells by PCR supports the hypothesis that these mast cells have specific binding sites for these cytokines. Transcripts of the expected sizes for either G-CSF R or ~~fins,~'.'' which are known to be expressed in granulocytes and macrophages, respectively, were not detected. This indicates that the cultured mast cells used for this experiment were pure and that the mRNAs of IL-3 R, IL-4 R, IL-S R, and IL-6 R detected by PCR were derived from mast cells. Our results in the binding assay of IL-3 R were contrary to those reported by Valent et al. '7 The reason for the discrepancy is not clear, but there are two possible explanations. The first possibility is that there are subtypes of human mast cells and that these cultured mast cells express IL-3 binding sites, whereas there are no IL-3 binding sites on either natural human lung mast cells or the HMC-I cell line. The second possibility is that human mast cells express extremely low numbers of IL-3 binding sites that are not easily detectable by binding assay. Indeed, we used a larger number of cells and higher radioactivity of labeled IL-3 than did Valent et al." Kirshenbaum et previously showed that IL-3 alone and in combination with SCF promoted the development of human mast cells from CD34' bone marrow cells and that the mast cells developed in the presence of IL-3 alone were immature. Durand et al"" also reported recently that human mast cells were generated in serum-free cultures of CD34' cord blood cells in the presence of SCF and IL-3. These mast cells remained immature in morphology and died in the absence of either SCF or IL-3. It is possible that IL-3 R might be highly expressed on immature human mast cells and their progenitors and that the expression of IL-3 R might decrease during the maturation of human mast cells.
In conclusion, we investigated the effects of IL-3, IL-4, IL-5, and IL-6 as well as SCF in vitro on the survival of human mast cells developed from cord blood mononuclear cells in the presence of SCF and L-6. These cytokines, with the exception of IL-3, enhanced IgE-mediated histamine release. In addition, the findings of RT-PCR and binding assays suggested that these human mast cells express specific receptors for each cytokine. These cytokines, which are mainly produced by Th2 lymphocytes, might regulate the functions of human mast cells in allergic reactions.
